Author Correction: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Sci Rep. 2022 Jan 17;12(1):1147. doi: 10.1038/s41598-022-05489-0.

Adam Lauko¹, Rupesh Kotecha^{2

3}, Addison Barnett⁴, Hong Li⁵, Vineeth Tatineni⁶, Assad Ali⁴, Pradnya Patil⁷, Alireza M Mohammadi^{1

4

8}, Samuel T Chao^{4

9}, Erin S Murphy^{4

9}, Lilyana Angelov^{1

4

8}, John H Suh^{4

9}, Gene H Barnett^{1

4

8}, Nathan A Pennell⁷, Manmeet S Ahluwalia^{10

11}

¹ Case Western Reserve University School of Medicine MSTP, Cleveland, OH, USA.
² Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
³ Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
⁴ Rosa Ella Burkhart Brain Tumor and Neuro-Oncology Center, Taussig Cancer Institute, Cleveland, OH, USA.
⁵ Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
⁶ Department of Internal Medicine, Summa Health, Akron City Hospital, Akron, OH, USA.
⁷ Department of Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
⁸ Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
⁹ Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
¹⁰ Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA. manmeeta@baptisthealth.net.
¹¹ Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, 8900 North Kendall Drive, Miami, FL, 33176, USA. manmeeta@baptisthealth.net.

No abstract available

Publication types